Century Therapeutics Inc (IPSC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$2.03-1.93%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
Century Therapeutics leads in off-the-shelf cell therapy for cancer. Management aims to submit the CNTY-813 IND by Q4 2026. Revenue has held steady at about $109 million despite biotech challenges. Recent earnings beats show improving execution.
The company remains unprofitable with no revenue growth for over a year. Analysts expect continued losses with no revenue growth in the near term. The biotech sector is risky and the company faces elevated risks and a stormy market.
The market expects about 100% revenue growth, but the company has shown stagnant revenue at $109 million. Our fair value near $15.68 implies optimism, but the company is still loss-making and behind on growth targets.
Breaks if: IND submission delayed beyond 2026-Q4
Complete IND submission for CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, targeting 4Q 2026 with initial clinical data expected in 2H 2027.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently in a development stage, focusing on advancing clinical trials and submitting regulatory applications, but it is experiencing operating losses and heightened near-term risks.
The market appears to price IPSC as a company with a low fragility tier, suggesting that current valuations are justified compared to peers. However, there is a slight expectations gap, indicating that investors may anticipate modest improvements in performance.
Management is on track with key priorities, including the submission of CNTY-813 IND and the advancement of CNTY-308 clinical trials. However, the company remains loss-making, and its financial performance has recently declined, which could impact future results.
The long-term thesis hinges on several factors, including the company's ability to meet its clinical milestones and the overall performance of the healthcare sector. Additionally, any changes in guidance or economic conditions that affect investor sentiment could significantly impact the company's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. IPSC's recent financial performance dropped to the bottom half of its industry. This change reflects a decline in the company's standing. Additionally, the latest earnings report showed a significant miss.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Management consistently reports CNTY-813 IND submission on track for 4Q 2026 with initial clinical data expected in 2H 2027. This aligns with the recent FDA pre-IND meeting and established Phase 1 manufacturing process, indicating delivery on the stated timeline.
“IND submission on track for 4Q 2026; initial clinical data expected in 2H 2027”
“CNTY-813 IND submission on track for 4Q 2026; initial clinical data expected in 2H 2027”
“CNTY-813 remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027”
Breaks if: EPS loss worsens beyond -$0.50 per share in FY26
Breaks if: Revenue falls below $100 million in any quarter
Management aims to maintain revenue levels at approximately $109 million.
Over the next 1 to 3 years, IPSC's prospects will depend on its execution of clinical milestones and the broader market environment. Not investment advice.